IMMUNOLOGIC APPROACHES TO THE THERAPY OF HIV-1 INFECTION

人们集中精力研究 人类免疫缺陷免疫学方法的治疗方面 艾滋病毒（HIV）感染和获得性免疫缺陷综合症。 利用外周血淋巴细胞和骨的连续免疫疗法 来自gp 160致敏的同基因供体的骨髓与联合 继续使用抗逆转录病毒药物。 三位获奖者之一 表明过继转移后CD 4计数持续升高。 一项I期临床试验将nef特异性CTL克隆给予其受体， 开始IL-2输注供体。 CTL输注良好， 耐受，并观察到适度的抗逆转录病毒活性。 活性 免疫治疗方案利用gp 160和p24免疫原， 血清阳性患者继续治疗。 两种重组蛋白均为 耐受性良好并产生淋巴增殖反应。 研究 产生人免疫球蛋白基因的随机重组文库 从艾滋病毒感染者开始， 用于被动免疫治疗的单克隆抗体。 I期研究 齐多夫定（ZDV）和白细胞介素-2（IL-2）的组合， 继续使用干扰素-α和IL-2。 的最大耐受剂量 当与ZDV一起施用时，已经定义了IL-2，并且该研究已经完成。 修改以评估免疫学和抗病毒作用的 反复服用这些药物。 一项评估 N-乙酰半胱氨酸的安全性和药代动力学研究已接近完成。 没有观察到新的毒性，口服生物利用度似乎如此 低到口服给药可能不切实际。 没有抗逆转录病毒的效果 被人看见了

An intensive effort was directed toward studying the potential therapeutic aspects of immunologic approaches to human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome. Adoptive immunotherapy utilizing peripheral blood lymphocytes and bone marrow from gpl60-primed syngeneic donors in association with combination antiretroviral agents was continued. One of three recipients demonstrated persistent elevations in CD4 counts after adoptive transfer. A phase I clinical trial administering a nef-specific CTL clone to its donor with IL-2 infusions was initiated. The CTL infusions were well tolerated, and modest antiretroviral activity was observed. Active immunotherapy protocols utilizing gpl60 and p24 immunogens in seropositive patients were continued. Both recombinant proteins were well tolerated and produced lymphoproliferative responses. A study generating random recombinatorial libraries of human immunoglobulin genes from HIV infected individuals was initiated in an effort to produce human monoclonal antibodies for use in passive immunotherapy. Phase I studies of the combinations of zidovudine (ZDV) and interleukin-2 (IL-2) and interferon-alpha and IL-2 were continued. The maximum tolerated dose of IL-2 when administered with ZDV has been defined, and the study has been modified to evaluate the immunologic and antiviral effects of the repeated administration of these agents. A protocol evaluating the safety and pharmacokinetics of N-acetylcysteine is nearing completion. No new toxicities have been observed, and oral bioavailability appears so low that oral dosing may be impractical. No antiretroviral effects have been seen.